When will Teriflunomide be included in medical insurance?

Teriflunomide (Teriflunomide) is a prescription drug that is a type of immunomodulator that reduces the symptoms and disease progression of multiple sclerosis by inhibiting the activity of specific immune cells. It reduces the number of white blood cells, thereby reducing the immune system's attack on nervous tissue and slowing the progression of the disease.

Multiple sclerosis (MS) is an autoimmune disease that mainly affects the central nervous system, causing neuronal damage and inflammatory reactions. In MS, certain types of white blood cells play a role in destroying myelin, the protective sheath that surrounds nerve fibers and helps nerve signals, or information, flow efficiently between the brain and parts of the body. Teriflunomide's mechanism of action involves inhibiting dihydroxyacetyl dehydrogenase (DHODH), which blocks the DNA synthesis process and reduces the activity of immune cells such as T lymphocytes and B lymphocytes. It also has anti-inflammatory properties that can reduce inflammatory responses and related symptoms.

The original drug Teriflunomide has been marketed in China and has entered the scope of medical insurance through medical insurance reimbursement standards. It may be limited to multiple sclerosis patients who are ineffective in conventional treatments. However, the reimbursement ratio is different in different regions, and the price after reimbursement is different. Specifications The price of 14mg*28 tablets per box is around 10,000 yuan, which is expensive. Cheaper generic drugs are also sold in other overseas countries. The pharmaceutical ingredients of generic drugs are basically the same as those of the original drugs. The price of each box of 14mg*30 tablets produced by an Indian pharmaceutical factory is around RMB 800 (the price may fluctuate due to exchange rates).